Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results
Theriva Biologics, Inc. (TOVX)
Company Research
Source: GlobeNewswire
Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma Manufacturing funding awarded by the Spanish Government’s National Knowledge Transfer Program Data and Safety Monitoring Committee Review of Phase 1b/2a SYN-004 in allogeneic hematopoietic cell transplant recipients recommends expansion to Cohort 3 Orphan Medicinal Product Designation granted by the European Commission to VCN-01 for the treatment of retinoblastoma Rare Pediatric Disease Designation granted by the FDA for the treatment of retinoblastoma Placed Second in International Competition for Merck KGaA’s EMEA Advance Biotech Grant ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reporte
Show less
Read more
Impact Snapshot
Event Time:
TOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TOVX alerts
High impacting Theriva Biologics, Inc. news events
Weekly update
A roundup of the hottest topics
TOVX
News
- SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]Yahoo! Finance
- Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]Seeking Alpha
- Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantGlobeNewswire
- Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of RetinoblastomaGlobeNewswire
- Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]Seeking Alpha
TOVX
Analyst Actions
- 11/13/24 - Maxim Group
TOVX
Sec Filings
- 11/20/24 - Form S-8
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- TOVX's page on the SEC website